Hemodialysis-associated left ventricular dysfunction: identification of dialysis-induced triggers, prevalence and prognostic impact.

Hemodialysis-associated left ventricular dysfunction: identification of dialysis-induced triggers, prevalence and prognostic impact. - HD-associated LV dysfunction

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33776

Enrollment

120

Registered

2009-02-27

Start date

2009-04-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left ventricular dysfunction

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult (age >=18 years old) maintenance hemodialysis patients.

Exclusion criteria

Exclusion criteria: Pre-existing severe (New York Heart Association class IV) left ventricular systolic failure or inadequate echocardiographical windows to obtain images of sufficient quality.

Design outcomes

Primary

Measure	Time frame
The prevalence of HD-associated LV dysfunction as assessed by pre-, intra-, and post-HD echocardiography.	—

Secondary

Measure	Time frame
To elucidate the mechanisms/ pathways that are pathophysiologically involved in HD-associated LV dysfunction we will relate its occurrence to pre-HD levels and intra-HD alterations in biomarkers of the inflammatory response (hsCRP, IL-6, pentraxin III), oxidative stress (SOD, MDA, AGEs), bioincompatibility (complement, leukocytes), endothelial dysfunction/ activation (von Willebrand factor), and with autonomic dysfunction (HRV). The choice for these pathways is based on their likely role in both the regulation of MBF and the increased risk of adverse cardiac events. Finally, we will evaluate the outcome of this cohort during a 2-year follow-up and analyse for the prognostic impact of LV dysfunction on predefined cardiovascular events and changes in LV function by repeat echocardiography at 1 year and at 2 years.	—

Measure

Time frame

To elucidate the mechanisms/ pathways that are pathophysiologically involved in HD-associated LV dysfunction we will relate its occurrence to pre-HD levels and intra-HD alterations in biomarkers of the inflammatory response (hsCRP, IL-6, pentraxin III), oxidative stress (SOD, MDA, AGEs), bioincompatibility (complement, leukocytes), endothelial dysfunction/ activation (von Willebrand factor), and with autonomic dysfunction (HRV). The choice for these pathways is based on their likely role in both the regulation of MBF and the increased risk of adverse cardiac events. Finally, we will evaluate the outcome of this cohort during a 2-year follow-up and analyse for the prognostic impact of LV dysfunction on predefined cardiovascular events and changes in LV function by repeat echocardiography at 1 year and at 2 years.

—

Countries

Netherlands

Outcome results